Processing...
All Trials
Search
Search
There are 1803 active trials in our database.
Click on a trial to see more information.
1803 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced or metastatic solid tumors that are refractory to, have progressed after, or are intolerant to standard therapies may receive oral AMXI-5001, a novel dual PARP1/2 and microtubule polymerization inhibitor, as monotherapy in this open-label study. Participants must have ECOG 0-1 and measurable or evaluable disease; no concurrent cancer therapy or strong CYP3A4 modulators are allowed.
ClinicalTrials.gov ID: NCT04503265
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including expansion cohorts for triple-negative breast cancer or gastric/gastroesophageal junction cancer) refractory to standard therapies, and patients with relapsed/refractory acute myeloid leukemia, to evaluate the safety and preliminary efficacy of BAL0891, a dual TTK/PLK1 mitotic checkpoint inhibitor, as monotherapy or in combination with carboplatin or paclitaxel.
ClinicalTrials.gov ID: NCT05768932
TrialFetch AI summary: This trial enrolls adults with unresectable locally advanced or metastatic solid tumors—including colorectal, triple-negative breast, melanoma, and ovarian cancer—who have progressed on or cannot receive standard therapies, to receive NM1F (a PVRIG/CD112R immune checkpoint inhibitor) alone or in combination with pembrolizumab. Key exclusions are active CNS involvement, prior PVRIG/CD226-axis therapy, and significant comorbidities.
ClinicalTrials.gov ID: NCT05746897
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors—primarily colorectal cancer but also including HCC, TNBC, NSCLC, ovarian cancer, melanoma, cholangiocarcinoma, and synovial sarcoma—who have progressed on or are ineligible for standard treatments. Patients receive intravenous ST316, a β-catenin/BCL9 interaction inhibitor targeting aberrant WNT/β-catenin signaling, as monotherapy or in combination with standard regimens in CRC.
ClinicalTrials.gov ID: NCT05848739
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have exhausted standard therapies and provides investigational monotherapy with RSC-1255, an oral small-molecule inhibitor of V-ATPase targeting both mutant and wild-type RAS, with enhanced potency against KRAS-G13D and KRAS-G12V mutations. All participants receive RSC-1255, and no control arm is included.
ClinicalTrials.gov ID: NCT04678648
TrialFetch AI summary: Enrolling adults (≥18; ≥16 for high-risk neuroblastoma or sarcoma) with measurable, GD2-positive recurrent/metastatic solid tumors (e.g., SCLC, high-risk neuroblastoma, sarcomas, melanoma) with ECOG 0–1 and adequate organ function. Two-step pretargeted radioimmunotherapy: IV GD2-SADA bispecific fusion protein (targets GD2; self-assembling/disassembling to enhance tumor avidity and renal clearance) followed after a set interval by 177Lu-DOTA to deliver beta radiation to tumor-retained antibody; dose-escalation with repeat cycles allowed.
ClinicalTrials.gov ID: NCT05130255
TrialFetch AI summary: Adults with incurable, locally advanced or metastatic solid tumors (e.g., NSCLC, HNSCC, melanoma, TNBC, GI, cervical, CRC, urothelial, clear cell RCC, HCC) receive RO7502175, an afucosylated anti-CCR8 IgG1 designed to deplete intratumoral Tregs via enhanced ADCC, as monotherapy or combined with PD-(L)1 inhibitors (atezolizumab or pembrolizumab). Eligible patients have ECOG 0–1, measurable disease, and no active infections, autoimmune disease, or untreated CNS metastases.
ClinicalTrials.gov ID: NCT05581004
TrialFetch AI summary: Adults with recurrent or rare primary CNS tumors (e.g., GBM, diffuse midline glioma, ependymoma, medulloblastoma, atypical/anaplastic meningioma) after standard therapy receive oral ONC206 monotherapy. ONC206 is an imipridone that non-competitively antagonizes DRD2/DRD3 and allosterically hyperactivates mitochondrial ClpP, aiming to trigger integrated stress response and apoptosis; dose-escalation with food-effect/PK assessment and potential expansion at RP2D.
ClinicalTrials.gov ID: NCT04541082
TrialFetch AI summary: Pediatric patients (12 months–21 years) with relapsed/refractory solid tumors or lymphoma, including CNS tumors; Phase 2 focuses on progressive/recurrent DIPG or other H3 K27–altered diffuse midline gliomas post-radiation. Single-arm IV CBL0137 (a FACT “chromatin-trapping” agent that activates p53, suppresses NF-κB, and induces interferon response) is given on Days 1 and 8 of 21-day cycles to define RP2D and assess antitumor activity.
ClinicalTrials.gov ID: NCT04870944
TrialFetch AI summary: For pediatric and adult patients with relapsed/refractory high-risk neuroblastoma/ganglioneuroblastoma or osteosarcoma, after standard therapies. Patients receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GD2-directed CAR T cells engineered to co-express IL-15 (to enhance persistence/function) and an inducible caspase-9 safety switch.
ClinicalTrials.gov ID: NCT03721068